Fentanyl sublingual: In breakthrough pain in opioid-tolerant adults with cancer

Drugs

Volumn 70, Issue 17, 2010, Pages 2281-2288

  Chwieduk, Claudine M ^a   McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Cancer pain; Fentanyl, general; Sublingual

Indexed keywords

ABSTRAL; FENTANYL; PLACEBO; RAPINYL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIA; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG TOLERABILITY; DYSPNEA; FEVER; HEADACHE; HUMAN; NAUSEA; PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; REVIEW; SOMNOLENCE; TABLET; VOMITING;

ADMINISTRATION, SUBLINGUAL; ADULT; ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; FENTANYL; HUMANS; NEOPLASMS; PAIN, INTRACTABLE;

EID: 78449309343     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11200910-000000000-00000     Document Type: Review

References (32)

1. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain:characteristics and impact in patients with cancer pain. Pain 1999 May; 81 (1-2): 129-34.
2. Fine PG. Breakthrough cancer pain: epidemiology, char-acteristics and management. CNS Drugs 2000 May; 13: 313-9.
3. Miaskowski C, Cleary J, Burney R, et al. American PainSociety guideline for the management of cancer pain in adults and children [online]. Available from URL: http:// www.guidelines.gov/summary/summary.aspx?doc-id=7297 [Accessed 2010 Oct 11].
4. Scottish Intercollegiate Guidelines Network. Control ofpain in adults with cancer [online]. Available from URL http://www.sign.ac.uk/pdf/qrg106.pdf [Accessed 2010 Oct 11].
5. Portenoy RK, Lesage P. Management of cancer pain. Lan-cet 1999 May 15; 353 (9165): 1695-700.
6. Mercadante S, Fulfaro F. World Health Organizationguidelines for cancer pain: a reappraisal. Ann Oncol 2005 May; 16 Suppl.: iv132-5.
7. Hanks GW, de Conno F, Cherny N, et al. Morphine andalternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 Mar 2; 84 (5): 587-93.
8. Davies AN, Dickman A, Reid C, et al. The management ofcancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13 (4): 331-8.
9. Christrup LL, Lundorff L, Werner M. Novel formulationsand routes of administration for opioids in the treatment of breakthrough pain. Therapy 2009; 6 (5): 695-706.
10. Blick SKA, Wagstaff AJ. Fentanyl buccal tablet: in break-through painin opioid-tolerant patients with cancer. Drugs 2006; 66 (18): 2387-93.
11. William L, MacLeod R. Management of breakthrough painin patients with cancer. Drugs 2008; 68 (7): 913-24.
12. Grape S, Schug SA, Lauer S, et al. Formulations of fentanylfor the management of pain. Drugs 2010; 70 (1): 57-72.
13. Electronic Medicines Compendium. Abstral sublingual ta-blets: summary of product characteristics [online]. Available from URL: http://emc.medicines.org. uk/medicine/ 21371/SPC/Abstral+Sublingual+Tablets/ [Accessed 2010 Oct 11].
14. ProStrakan Group. ProStrakan announces FDA acceptanceof Abstral filing [media release]. 2009 Oct 6.
15. Jeal W, Benfield P. Transdermal fentanyl: a review of itspharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53 (1): 109-38.
16. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an up-dated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61 (15): 2289-307.
17. Hair PI, Keating GM, McKeage K. Transdermal matrixfentanyl membrane patch (Matrifen®): in severe cancer-related chronic pain. Drugs 2008; 68 (14): 2001-9.
18. Narita M, Imai S, Itou Y, et al. Possible involvement of JJ,1-opioid receptors in the fentanyl- or morphine-induced an-tinociception at supraspinal and spinal sites. Life Sci 2002 Apr 5; 70 (20): 2341-54.
19. Maguire P, Tsai N, Kamal J, et al. Pharmacological profilesof fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 Mar 24; 213 (2): 219-25.
20. Bilfinger TV, Fimiani C, Stefano GB. Morphine's im-munoregulatory actions are not shared by fentanyl. Int J Cardiol 1998 Apr; 64 Suppl. 1: 61-6.
21. Rosow CE, Moss J, Philbin DM, et al. Histamine releaseduring morphine and fentanyl anesthesia. Anesthesiology 1982; 56 (2): 93-6.
22. Bovill JG. Which potent opioid? Important criteria for se-lection. Drugs 1987; 33: 520-30.
23. Megens AAHP, Artois K, Vermeire J, et al. Comparison ofthe analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998; 15 (4): 253-7.
24. Bredenberg S, Duberg M, Lennernas B, et al. In vitro and invivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003; 20 (3): 327-34.
25. Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sub-lingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomised phase II study. Palliat Med 2010 Apr; 24: 286-93.
26. Williams DA, Foye WO, Lemke TL. Foye's principles ofmedicinal chemistry. 5th ed. Baltimore (MD): Lippincott Williams and Wilkins, 2002.
27. Lennernas B, Hedner T, Holmberg M, et al. Pharmaco-kinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005 Feb; 59 (2): 249-53.
28. Lorch U, Farrell F, Kilborn J, et al. Pharmacokinetics andtolerability of sublingual fentanyl in healthy Japanese and Caucasian volunteers: phase I, open-label single-dose study. Proceedings of the 13th International Pain Clinic Congress; 2008 May 29-Jun 1; Seoul, 131-5.
29. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-termtolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009 Oct 8; 25 (12): 2877-85.
30. Zeppetella G. Sublingual fentanyl citrate for cancer-relatedbreakthrough pain: a pilot study. Palliat Med 2001 Jul; 15 (4): 323-8.
31. Danjoux C, Franssen E, Chow E, et al. Sublingual fentanylcitrate for control of breakthrough pain in patients referred for palliative radiotherapy. Curr Oncol 2004; 11 (1): 3-7.
32. Nalamachu S, Howell J, Derrick R. Long-term safety and tolerability of sublingual fentanyl [poster]. American Academy of Pain Medicine 25th Annual Meeting; 2009 Jan 28-31; Honolulu (HI)